期刊
HEADACHE
卷 55, 期 3, 页码 439-441出版社
WILEY
DOI: 10.1111/head.12498
关键词
botulinum toxin; migraine; pain location; treatment; trigemino-autonomic reflex; unilateral cranial autonomic symptom
资金
- Merck
- Janssen Pharmaceutical Products
- Lusofarmaco
- Allmiral
- Allergan
Most pharmacological trials deal with migraine as if it were a clinically homogeneous disease, and when detailing its characteristics, they usually report only the presence, or absence, of aura and attack frequency but provide no information on pain location, a non-trivial clinical detail. The past decade has witnessed growing emerging evidence suggesting that individuals with unilateral pain, especially those with associated unilateral cranial autonomic symptoms, are more responsive than others to trigeminal-targeted symptomatic and preventive therapy with drugs such as triptans or botulinum toxin. A simple way for migraine research treatment to take a step forward might be to step back, reappraise, and critically evaluate easily obtainable patient-reported clinical findings along with current knowledge on pain features.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据